Last €67.14 EUR
Change Today +1.26 / 1.91%
Volume 41.5K
MOR On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 9:52 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MOR) Snapshot

Open
€66.10
Previous Close
€65.88
Day High
€67.36
Day Low
€65.96
52 Week High
03/6/14 - €72.72
52 Week Low
07/26/13 - €49.46
Market Cap
1.8B
Average Volume 10 Days
55.5K
EPS TTM
€0.30
Shares Outstanding
26.3M
EX-Date
--
P/E TM
223.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for MORPHOSYS AG (MOR)

Related News

No related news articles were found.

morphosys ag (MOR) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MOR) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies. The company’s proprietary programs include MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR202 and MOR208 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the development and co-promotion of the CD38 cancer program. The company was founded in 1992 and is headquartered in Martinsried, Germany.

310 Employees
Last Reported Date: 04/29/14
Founded in 1992

morphosys ag (MOR) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €772.6K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €524.1K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €524.1K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €524.1K
Compensation as of Fiscal Year 2013.

morphosys ag (MOR) Key Developments

MorphoSys Signs Co-Development and License Agreement with Merck

MorphoSys has signed a co-development and license agreement with Merck. The contract has been signed in an effort to discover and develop therapeutic antibodies against undisclosed immune checkpoints. Under the contract, both firms' biopharmaceutical divisions, will join forces to develop therapies that modulate the immune system's natural ability to combat tumours. The transaction will see MorphoSys apply its Ylanthia antibody phage library and technology platform to discover antibodies against the targets of interest. MorphoSys will co-fund research and development costs with the option to opt-out at predefined stages, while Merck Serono will have sole responsibility for commercialising of any resulting products.

Morphosys AG and Merck Serono Signe an Agreement to Discover and Develop Therapeutic Antibodies Against Undisclosed Immune Checkpoints

MorphoSys AG and Merck Serono announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. Under the terms of the agreement, MorphoSys AG and Merck Serono will join forces to develop therapies that immune syaytem's join forces to develop therapies that modulate the immune system's natural ability to fight tumors. MorphoSys MorphoSys will apply its proprietary Ylanthia antibody phage library and technology platform to identify antibodies against the targets of interest. Merck Serono with its strong portfolio and capabilities in the field of immuno-oncology and clinical development will be fully responsible for execution of development from Phase 1 onwards.

Morphosys AG Presents at DbAccess German, Swiss & Austrian Conference 2014, Jun-13-2014 09:30 AM

Morphosys AG Presents at DbAccess German, Swiss & Austrian Conference 2014, Jun-13-2014 09:30 AM. Venue: Hotel Adlon Kempinski, Berlin, Germany. Speakers: Jens Holstein, Chief Financial Officer and Member of Management Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €67.14 EUR +1.26

MOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $166.74 USD +3.37
Intrexon Corp $22.41 USD +0.02
XOMA Corp $4.10 USD +0.07
View Industry Companies
 

Industry Analysis

MOR

Industry Average

Valuation MOR Industry Range
Price/Earnings 100.0x
Price/Sales 22.1x
Price/Book 4.9x
Price/Cash Flow 264.7x
TEV/Sales 18.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit www.morphosys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.